"Viral Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.
| Descriptor ID |
D014765
|
| MeSH Number(s) |
D20.215.894.899
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Viral Vaccines".
Below are MeSH descriptors whose meaning is more specific than "Viral Vaccines".
This graph shows the total number of publications written about "Viral Vaccines" by people in this website by year, and whether "Viral Vaccines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 6 | 1 | 7 |
| 1996 | 8 | 1 | 9 |
| 1997 | 4 | 1 | 5 |
| 1998 | 7 | 2 | 9 |
| 1999 | 7 | 2 | 9 |
| 2000 | 5 | 1 | 6 |
| 2001 | 5 | 2 | 7 |
| 2002 | 8 | 2 | 10 |
| 2003 | 8 | 0 | 8 |
| 2004 | 6 | 4 | 10 |
| 2005 | 4 | 5 | 9 |
| 2006 | 7 | 0 | 7 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 2 | 0 | 2 |
| 2012 | 3 | 2 | 5 |
| 2013 | 1 | 0 | 1 |
| 2014 | 4 | 1 | 5 |
| 2015 | 3 | 1 | 4 |
| 2016 | 3 | 2 | 5 |
| 2017 | 4 | 1 | 5 |
| 2018 | 1 | 3 | 4 |
| 2019 | 4 | 3 | 7 |
| 2020 | 14 | 3 | 17 |
| 2021 | 5 | 2 | 7 |
| 2022 | 10 | 1 | 11 |
| 2023 | 4 | 0 | 4 |
| 2024 | 2 | 3 | 5 |
| 2025 | 8 | 0 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Viral Vaccines" by people in Profiles.
-
Community willingness to participate in a Nipah vaccine trial in Bangladesh. Vaccine. 2025 Aug 30; 62:127578.
-
Identification of the seven critical residues that control ZIKV-DENV cross-reactivity to engineer a non-cross-reactive ZIKV vaccine. Cell Rep. 2025 Aug 26; 44(8):116098.
-
Marburg virus glycoprotein mRNA vaccine is more protective than a virus-like particle-forming mRNA vaccine. J Clin Invest. 2025 Sep 02; 135(17).
-
Divergent antibody recognition profiles are generated by protective mRNA vaccines against Marburg and Ravn viruses. Nat Commun. 2025 Jul 01; 16(1):5702.
-
Safety, immunogenicity, and effectiveness of chikungunya vaccines in pregnant persons, children, and adolescents: a protocol for a living systematic review and meta-analysis. Reprod Health. 2025 Apr 18; 22(1):56.
-
Safety, immunogenicity, efficacy, and effectiveness of Lassa fever vaccines in pregnant persons, children, and adolescents: a protocol for a living systematic review and meta-analysis. Reprod Health. 2025 Apr 15; 22(1):53.
-
Umbrella review of the safety of Chikungunya vaccine platforms used in other vaccines. Hum Vaccin Immunother. 2025 Dec; 21(1):2463191.
-
Norovirus replication, host interactions and vaccine advances. Nat Rev Microbiol. 2025 Jun; 23(6):385-401.
-
Correlation of Genogroup I, Genotype 1 (GI.1) Norovirus Neutralizing Antibody Levels With GI.1 Histo-Blood Group Antigen-Blocking Antibody Levels. J Infect Dis. 2024 Dec 16; 230(6):1376-1379.
-
Burden of Lassa fever disease in pregnant women and children and options for prevention. Vaccine. 2025 01 01; 43(Pt 1):126479.